Journey Medical Corp

NASDAQ:DERM USA Drug Manufacturers - Specialty & Generic
Market Cap
$204.42 Million
Market Cap Rank
#17210 Global
#6548 in USA
Share Price
$7.50
Change (1 day)
+0.67%
52-Week Range
$5.57 - $9.26
All Time High
$9.50
About

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a top… Read more

Journey Medical Corp - Asset Resilience Ratio

Latest as of September 2019: 64.93%

Journey Medical Corp (DERM) has an Asset Resilience Ratio of 64.93% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$283.23 Million
Cash + Short-term Investments
Total Assets
$436.24 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2018)

This chart shows how Journey Medical Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Journey Medical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $283.23 Million 64.93%
Total Liquid Assets $283.23 Million 64.93%

Asset Resilience Insights

  • Very High Liquidity: Journey Medical Corp maintains exceptional liquid asset reserves at 64.93% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Journey Medical Corp Industry Peers by Asset Resilience Ratio

Compare Journey Medical Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
Drug Manufacturers - Specialty & Generic -0.02%
Kamada
NASDAQ:KMDA
Drug Manufacturers - Specialty & Generic 21.63%
Dongwha Pharm.Co.Ltd
KO:000020
Drug Manufacturers - Specialty & Generic 1.92%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.46%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%
Kotra Industries Bhd
KLSE:0002
Drug Manufacturers - Specialty & Generic 9.82%
Yuyu Pharma Inc
KO:000227
Drug Manufacturers - Specialty & Generic 1.74%

Annual Asset Resilience Ratio for Journey Medical Corp (2014–2018)

The table below shows the annual Asset Resilience Ratio data for Journey Medical Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-12-31 60.43% $208.06 Million $344.32 Million +14.94pp
2017-12-31 45.48% $255.07 Million $560.79 Million -21.74pp
2016-12-31 67.23% $210.15 Million $312.60 Million +18.81pp
2015-12-31 48.42% $107.45 Million $221.93 Million +24.97pp
2014-12-31 23.45% $41.79 Million $178.22 Million --
pp = percentage points